Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.

PRNewsWire • 8 hours ago

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Zacks Investment Research • Oct 9, 2026

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

PWS-VISTA observational study will build longitudinal real-world evidence on VYKAT XR use for hyperphagia in Prader-Willi syndrome in routine clinical practice BRAVE-PWS observational study will capture caregiver-reported information to better understand the experience and burden of caring for someone with Prader-Willi syndrome Integrated analysis will further evaluate adverse events of special interest — including fluid retention, hyperglycemia, hirsutism and hypertrichosis — during VYKAT XR treatment SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and expanding clinical and real-world evidence for VYKAT® XR (diazoxide choline) extended-release tablets will be presented at the Foundation for Prader-Willi Research (FPWR) 2026 Annual Research Symposium & Family Conference, taking place Oct. 7-10 in Philadelphia.

PRNewsWire • Sep 30, 2026

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W.

PRNewsWire • Sep 28, 2026

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.

MarketBeat • Sep 23, 2026

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha • Sep 10, 2026

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • Sep 9, 2026

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

PRNewsWire • Sep 2, 2026

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.

Zacks Investment Research • Aug 31, 2026